← All trials
NCT05382871
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 27, 2022
- Primary completion
- Nov 27, 2022
- Completion date
- Nov 27, 2023
- First posted
- May 19, 2022
- Last posted
- Jun 2, 2022
- Enrollment
- 1800
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- The University of Hong KongCollaborator
- The University of Hong KongOverall official - principal investigator
- Beijing Tiantan Bio Co., LtdCollaborator
- Wuhan Institute of Biological Products Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.